TSND-201 for PTSD

(EMPOWER-2 Trial)

This trial tests a new treatment called TSND-201 to determine its safety and effectiveness for people with PTSD, a condition where past trauma affects daily life. Participants will receive either one of two doses of TSND-201 or a placebo once a week for four weeks. The trial seeks adults who have experienced PTSD symptoms for at least six months and have not found success with other treatments. Participants must communicate well and not have other significant health issues. As a Phase 3 trial, this treatment represents the final step before FDA approval, offering a chance to contribute to a potentially groundbreaking PTSD therapy.

Research has shown that TSND-201 is generally safe and well-tolerated in studies for treating PTSD. Headache was the most common side effect, indicating that most participants did not experience serious adverse effects. These findings support the continued development of TSND-201 as a treatment option.¹²³⁴⁵

Unlike the standard treatments for PTSD, which often include psychotherapy and medications like SSRIs and SNRIs, TSND-201 offers a potentially new way of tackling the condition. TSND-201 is unique because it might target different pathways in the brain associated with stress response, which could lead to more effective management of PTSD symptoms. Researchers are excited about TSND-201 because it could provide faster relief and benefits where other treatments may take weeks or even months to show results. Additionally, the trial includes two different doses, which could help determine the most effective dosage with the least side effects.

Research has shown that TSND-201 could be very helpful for treating PTSD. In this trial, participants will receive either TSND-201 at one of two dose levels or a placebo. Earlier studies found that TSND-201 quickly and strongly reduces PTSD symptoms. By Day 64, participants in those studies showed an improvement of -9.64 points in the CAPS-5 score, which measures PTSD severity, compared to a placebo. Those who took TSND-201 experienced fewer symptoms than those who took a placebo, with noticeable improvements throughout the treatment. Additionally, TSND-201 was well tolerated, causing few side effects. These findings suggest that TSND-201 could be an effective and fast-acting treatment for PTSD.⁶⁷⁸⁹¹⁰